PD05-11 POTENTIAL BENEFIT OF ADDING ORAL 5-AMINOLEVULINIC ACID TO PELVIC RADIOTHERAPY USING A SYNGENIC MYC-CAP PROSTATE CANCER MODEL

INTRODUCTION AND OBJECTIVES:Radiotherapy-induced normal tissue damage in rectum and bladder remains the largest dose-limiting factor for treatment of prostate cancer (PCa). 5-aminolevulinic acid (A...